R-Pharm withdrew from the capital of Albiogen, a distributor of foreign equipment for genetic research
[ad_1]
The drug manufacturer R-Pharm, founded by businessman Alexei Repik, has left the capital of Albiogen, which specializes in the distribution of foreign high-tech equipment for genetic research. According to SPARK-Interfax, from June 23, 2023, 99% of the shares in it were transferred to A-gen. It, in turn, belongs in equal proportions to the general director of Albiogen Andrey Frolov and the minority shareholder of the distributor Alexander Yakovlevsky.
The representative of R-Pharma forwarded the questions of Vedomosti to Albiogen. According to Frolov, the company’s exit from the R-Pharm group of companies is associated with a reorganization of the business model, while the goals and objectives of the supplier will remain the same – the promotion of next-generation genetic research technologies.
[ad_2]
Source link
